24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
FALSOLIEVA 250 MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | FALSOLIEVA 250 MG |
|---|---|
| Composition | Fulvestrant Injection 250 MG |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
FALSOLIEVA 250 MG (Fulvestrant Injection 250 MG) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
FALSOLIEVA 250 MG (Fulvestrant Injection 250 mg) is a prescription anticancer medicine containing Fulvestrant 250 mg, a hormonal therapy used primarily in the treatment of hormone receptor-positive (HR-positive) breast cancer in postmenopausal women. Fulvestrant belongs to a class of medicines known as Selective Estrogen Receptor Degraders (SERDs), which work by blocking and reducing estrogen receptors on cancer cells.
Many breast cancer cells depend on estrogen to grow and multiply. Fulvestrant binds to estrogen receptors and accelerates their degradation, reducing the ability of cancer cells to receive estrogen signals. This action helps slow or stop the growth of hormone-sensitive breast cancer cells.
FALSOLIEVA 250 MG is commonly used in the treatment of advanced breast cancer, locally advanced breast cancer, and metastatic breast cancer. It may be prescribed alone or in combination with targeted therapies, depending on the patient's clinical condition and treatment plan.
The medicine is administered as an intramuscular injection under the supervision of qualified healthcare professionals experienced in oncology treatment.
FALSOLIEVA 250 MG is commonly prescribed for:
Manufactured according to stringent pharmaceutical quality standards, FALSOLIEVA 250 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Fulvestrant therapy require regular medical evaluations and monitoring to assess treatment response and overall health status.
Due to its proven effectiveness in hormone-sensitive breast cancer, FALSOLIEVA 250 MG remains an important component of modern breast cancer management.
FALSOLIEVA 250 MG (Fulvestrant Injection 250 mg) is primarily used in the treatment and management of hormone-sensitive breast cancer.
The medicine is widely used in patients with advanced hormone receptor-positive breast cancer.
Fulvestrant helps manage breast cancer that has spread to other parts of the body.
The medicine targets estrogen receptor-positive cancer cells.
It is commonly prescribed for hormone receptor-positive breast cancer patients.
Fulvestrant may be used with targeted anticancer medicines as part of comprehensive treatment protocols.
The medicine is a key component of hormone-based breast cancer treatment.
Treatment may help slow disease progression and improve outcomes.
Fulvestrant belongs to a class of medicines known as Selective Estrogen Receptor Degraders (SERDs).
FALSOLIEVA works by:
This mechanism helps control hormone-sensitive breast cancer and supports effective disease management.
Like all medicines, FALSOLIEVA 250 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Pain, swelling, or discomfort at the injection site may occur.
Patients may experience episodes of warmth or flushing.
Digestive discomfort may occur during treatment.
Weakness and tiredness are commonly reported.
Musculoskeletal discomfort may occur in some patients.
Mild to moderate headaches may develop.
Back discomfort may occur during therapy.
Reduced appetite may affect nutritional intake.
Changes in liver function tests may occur and require monitoring.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of FALSOLIEVA 250 MG (Fulvestrant Injection 250 mg) should always be determined by a qualified oncologist.
Treatment recommendations vary according to disease status.
Prior endocrine therapies may influence treatment planning.
Concurrent targeted therapies may affect treatment schedules.
Hepatic function may be considered during treatment.
The patient's health status helps guide therapy decisions.
Before starting treatment, inform your doctor if you have:
Patients receiving Fulvestrant therapy may require:
Patients should also disclose all prescription medicines, supplements, vitamins, and herbal products they are taking to avoid potential drug interactions.
Pregnant and breastfeeding women should not use this medicine unless specifically advised by a healthcare professional.
It is primarily used for the treatment of hormone receptor-positive advanced and metastatic breast cancer.
Fulvestrant is a hormonal therapy medicine that blocks and degrades estrogen receptors in breast cancer cells.
No. Fulvestrant is a hormone therapy (endocrine therapy), not a traditional chemotherapy medicine.
It blocks estrogen receptors and promotes their degradation, reducing hormone-driven cancer growth.
Yes. It is often used in combination with targeted anticancer medicines according to treatment guidelines.
Hair loss is generally less common than with traditional chemotherapy medicines.
Yes. Routine monitoring helps assess treatment effectiveness and safety.
Yes. This medicine should only be administered by qualified healthcare professionals experienced in oncology treatment.